ClinicalTrials.gg
Enrolling by invitationNCT06731582TAMINGUpdated Dec 12, 2024

Nicotinamide Supplementation in Glaucoma

A Phase 3 interventional study of Nicotinamide Tablet and Nicotinamide Placebo in Glaucoma, sponsored by Singapore Eye Research Institute. Enrolling by invitation at 2 sites in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by Singapore Eye Research Institute · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Mar 2024, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Glaucoma with a site in Singapore — 3 open to participants now, 4 under way, 1 of them phase 3. Glaucoma · Singapore.

Planned enrollment
2nd of 22
520 · median 68
Started
2024
with 1 other
Phase 3
7 of 28
1 open now
Registered
26th of 28
by date
Lead sponsor
6 of 28
Singapore Eye Research Institute

Among the 28 studies in Glaucoma with a site in Singapore, this one is the 2nd largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 in phase 3, and was the 26th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

3 of the 28 studies in Glaucoma with a site in Singapore are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Glaucoma with a site in Singapore, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if nicotinamide (NAM, vitamin B3) supplementation can delay glaucoma progression 30% above that achieved with conventional glaucoma treatment using topical medication. The main questions it aims to answer are:

Can NAM supplementation improve the visual function of patients with glaucoma measured by visual field perimetry?

Researchers will compare NAM to a placebo (a look-alike substance that contains no drug) to see if NAM works as an adjuvant in glaucoma treatment.

Participants will:

  • Take NAM or a placebo every day for 2 years
  • Visit the clinic once every 3-4 months for checkups and tests
Read the detailed description

520 subjects with glaucoma will be enrolled (260 per study arm) from Singapore National Eye Centre and National University Hospital Eye Clinic.

The TAMING Glaucoma Study is designed as a phase 3, randomised, placebo-controlled, double-masked, superiority trial with two parallel groups and a primary endpoint of change in visual field progression over two-three years.

Participants who are currently on NAM will be asked to stop taking the tablets for a month prior to screening visit.

The study duration and your follow-up will be approximately 2-3 years. Recruitment: All participants will be sent an e-consent form via email or provided in hard copy for them to read. Participants will be allowed to ask questions and be given as much time as they require to consider whether they would like to participate. It will be made clear that it will not influence their clinical care in any way whether they agree to participate or not or choose to withdraw from the study at any given time. Written informed consent will be sought from participants prior to screening. Participants will be recruited from public and private ophthalmology clinics at the SNEC and NUH ophthalmology outpatient clinics.Research staff will screen medical records/medical history of patients attending glaucoma clinics to identify potential participants. A study team member will approach eligible patients to explain the study in detail either in person.

Screening visit: At screening, a participant's ophthalmic history will be taken to determine whether they are eligible for the study based on the ophthalmic inclusion and exclusion criteria.

Randomisation: Randomisation will be performed as block randomisation, stratified by glaucoma sub-type and trial site, with a 1:1 allocation.

After baseline testing, participants will be allocated to NAM or placebo in a ratio 1:1 utilising block randomisation stratified by glaucoma subtype and trial site. One or both eligible eyes will be enrolled. Statistical corrections will be used for bilaterally in the final analysis.Web-based randomisation will be conducted through REDCap. Research staff involved in data collection or assessing outcomes, statisticians and participants will remain masked to treatment allocation. A unique code will be allocated to each participant rather than a fixed code for each treatment group such that the unblinding of one individual will not affect the study group as a whole. Participants in the treatment group will take NAM (1.5 g/day - 2 tablets with food) for the remainder of the study.

Blinding: After baseline testing, participants will be allocated to NAM or placebo in a ratio 1:1 utilising block randomisation stratified by glaucoma subtype and trial site. Both eyes will be enrolled. Research staff involved in data collection or assessing outcomes, statisticians and participants will remain masked to treatment allocation. The period of supplementation for both the treatment and placebo group would be for 24 months.

EMERGENCY UNBLINDING: To maintain the overall quality and legitimacy of the clinical trial, code breaks should occur only in exceptional circumstances when knowledge of the actual treatment is absolutely essential for further management of the patient. The Principal Investigator should be made aware of such circumstances.The Investigator is encouraged to maintain the blind wherever possible. The Investigator must report all code breaks (with reason) as they occur on their electronic CRF on REDCap. As unblinding may not necessarily be a reason for study drug discontinuation, the actual allocation should not be disclosed to the participant or other members of the research team.

Test procedures: Refraction, Central cornea thickness, best corrected visual acuity, Blood pressure measurement, Urine Pregnancy test, slit lamp biomicroscopy, intra ocularpressure measurement, visual field testing, Fundus imaging, optical coherence tomography, electroretinography (optional), blood sampling for liver tests - Alanine transaminase / aspartate aminotransferase (ALT/AST) and genetics testing , Patient reported outcome measures (PROMs) Questionaire, Health Economic Evaluation (optional).

Discontinuation / withdrawal: the investigator may withdraw a subject from the study treatment if he is in violation of the protocol, experiences a serious or intolerable adverse event, develops symtopms/ conditions listed in the exclusion criteria during the study, wishes to withdraw from treatment. The investigator will also withdraw allsubjects from the study treatment if the study is terminated. Individuals who discontinue the study treatment will be encouraged to continue in the study and complete the evaluations.They are free to withdraw from the study at any time upon their request or the request of their legally acceptable representative. When a subject withdraws from the study, the reasons for withdrawal will be recorded by the investigator. Whenever possible, all subjects who withdraw from the study prematurely will continue to undergo scheduled visits for study assessments (follow-up). Subjects who fail to return for study assessments will be contacted by the research team in an attempt to have them comply with the protocol, by two documented phone calls and one email. Subjects who withdraw will not be replaced and sample size calculation accounts for 15% attrition. If voluntary withdrawal occurs, the subject will be asked to continue scheduled evaluations, complete an end of study evaluation, and be given appropriate care under medical supervision until the symptoms of any adverse event resolve or the subject's condition becomes stable.

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • nicotinamide
  • vitamin B3
  • NAM
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ³ 21 years, with definitive, treated POAG, PACG including normal tension glaucoma, PDG, PXFG in one or both eyes.

    • Best-corrected visual acuity equal or better than 6/18
    • Reproducible visual field defect due to glaucoma (3 contiguous points at less than 5%) and severity of visual field loss, MD between -2 and -18 dB. This range includes people with moderate disease which optimises detection of progression.
    • Patients must have at least two prior 24-2 VF tests which meet \<16% FP and \<21% fixation loss.
    • Previous selective laser trabeculoplasty is acceptable (IOP-lowering laser treatment) if ³ 3 months prior or filtering surgery >6 months previously.
    • Normal liver function tests.
    • Those taking NAM already will undergo a 1-month bef

Exclusion criteria

Exclusion Criteria:

  • Patients with active liver disease or end stage renal failure.

    • Active use of allopurinol, carbamazepine, or primidone.
    • Visually significant cataracts (example, likely to require surgery within 2 years).
    • Cataract surgery in the last 3 months or glaucoma filtration surgery in last 6 months.
    • Conditions that may cause non-glaucomatous visual field defect (for example, severe ptosis, cerebrovascular accident, prior panretinal photocoagulation, and other retinal or central nervous system diseases).
    • Not able to complete study (for example, concurrent severe systemic disease).
    • History of cancer in the last 5 years.
    • Unable to give consent.
    • Inability to tolerate or take nicotinamide and/or pyruvate.
    • Women of Child Bearing Potential, pregnancy or lactation.
    • History of Hypotension
    • Blood Pressure measurement of less than 90/60(
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
520 participants (estimated)

Study arms

  • Experimental
    Nicotinamide

    1.5 grams/day (2 tablets of 750 mg each)

    Dietary Supplement: Nicotinamide Tablet

  • Placebo comparator
    Placebo

    2 tablets

    Dietary Supplement: Nicotinamide Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Deviation (MD)

    ≥ 30% reduction in visual field mean deviation progression measured over 2 years compared to current IOP-lowering treatments alone.

    Time frame: 2 years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jul 2027, 40 months after the start.

Of 33 phase 3 interventional studies under Glaucoma, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 12, 2024
StartActual
Mar 12, 2024
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2028
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06731582
Lead sponsor
Singapore Eye Research Institute
Collaborators
National University Hospital, Singapore, Singapore National Eye Centre
Responsible party
Sponsor
First posted
Dec 12, 2024
Start date
Mar 12, 2024
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Dec 12, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niacinamide

Start the discussion